Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6923257 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6831507 | 0.87 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6831510 | 0.87 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13525560 | 0.87 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4792208 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1086468 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4507925 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5110398 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6829747 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13979141 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351711-B2 | Tricyclic indanyls as integrin inhibitors | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2008-04-01 | — | — | US | disclosed |
| EP-1506779-B1 | (3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-acetic acid derivatives and related tricyclic indanyls as alphaVbeta3 and alphaVbeta5 integrin inhibitors for the treatment of cancer and unstable angina | JANSSEN PHARMACEUTICA NV (BE) | 2006-07-12 | — | — | EP | disclosed |
| EP-1506779-A1 | (3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-acetic acid derivatives and related tricyclic indanyls as alphaVbeta3 and alphaVbeta5 integrin inhibitors for the treatment of cancer and unstable angina | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004043921-A1 | NOVEL PROCESS FOR THE PREPARATION OF 4-ARYL-3-HYDROXYMETHYL-1-METHYLPIPERIDINES. | NATCO PHARMA LIMITED (IN) | 2004-05-27 | — | — | WO | disclosed |
| WO-2002032870-A1 | PROCESS OF THE PREPARATION OF 3-SUBSTITUTED-4-ARYL PIPERIDINE COMPOUNDS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-25 | — | — | WO | disclosed |
| WO-2001029032-A1 | PROCESS FOR THE PREPARATION OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-26 | — | — | WO | disclosed |
| US-6172233-B1 | Process for making paroxetine | SMITHKLINE BEECHAM PLC (GB) | 2001-01-09 | — | — | US | disclosed |